Nelfinavir Plasma Concentrations Are Low during Pregnancy
Clinical Infectious Diseases2004Vol. 39(5), pp. 736–740
Citations Over TimeTop 15% of 2004 papers
J. F. J. B. Nellen, Igor Schillevoort, F. W. N. M. Wit, Alina S Bergshoeff, M. H. Godfried, Kees Boer, J Lange, D.M. Burger, Jan M. Prins
Abstract
Plasma nelfinavir concentration ratios (CRs) were calculated for all pregnant (n=27) and nonpregnant (n=48) human immunodeficiency virus type 1-infected women receiving the drug who visited our outpatient clinic. In pregnant women, mean and median nelfinavir CRs were significantly lower (P=.02 and P=.04, respectively), and 51% of the CRs were below the clinically relevant threshold of 0.90, compared with 35% of the CRs in nonpregnant women. After we adjusted for confounders, we found that the mean nelfinavir CR was 34% lower in pregnant women (P=.02). With targeted interventions, subsequent CRs in pregnant women showed a significant increase (median increase, 0.31; P=.01).
Related Papers
- → Nelfinavir(1997)38 cited
- → Drug design: New inhibitors for HIV-1 protease based on Nelfinavir as lead(2007)14 cited
- → Nelfinavir mesylate(2000)25 cited
- → Maintaining the nelfinavir trough concentration above 0.8 mg/L improves virologic response in HIV-1–infected children(2004)25 cited
- → Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients(2000)12 cited